Show Summary Details
Page of

Effectiveness of Antipsychotics in the Treatment of Schizophrenia: CATIE Phase 1 

Effectiveness of Antipsychotics in the Treatment of Schizophrenia: CATIE Phase 1
Chapter:
Effectiveness of Antipsychotics in the Treatment of Schizophrenia: CATIE Phase 1
Author(s):

Chadrick Lane

, and Mohini Ranganathan

DOI:
10.1093/med/9780190625085.003.0039
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 October 2019

This chapter provides a summary of the landmark study Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Phase 1 of CATIE evaluated whether there are measurable differences in effectiveness between antipsychotics (risperidone vs. olanzapine vs. ziprasidone vs. quetiapine vs. perphenazine) in the treatment of patients with schizophrenia. Starting with that question, the chapter describes the fundamentals of the study, including funding, study location, inclusion and exclusion criteria, how many participants were included, research design, interventions, follow-up, endpoints, outcomes, as well as criticisms and limitations. The chapter briefly reviews other relevant studies and information, discusses implications, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.